Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
Kyle Registre's childhood dream of becoming a pilot can finally come true now that he says he's been cured of sickle cell complications.
Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...
Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...
Right now, approximately 20 billion red blood cells are busy travelling through your blood vessels. They are delivering oxygen to all the different ...
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback